Tetrous, Inc.
Biologic solutions to optimize enthesis reformation, EnFix® is the future of bone to tendon healing.
Funding history
About Tetrous, Inc.
How much funding has Tetrous, Inc. raised?
Tetrous, Inc. has raised $2.6M in total funding. The most recent round was Series A.
Where is Tetrous, Inc. headquartered?
Tetrous, Inc. is headquartered in Sherman Oaks, CA.
What does Tetrous, Inc. do?
Biologic solutions to optimize enthesis reformation, EnFix® is the future of bone to tendon healing.
What problem does Tetrous, Inc. solve?
The page states 20% to 70% of rotator cuff repairs structurally fail, and that existing augmentation products mainly use overlays/patches to reinforce the tendon rather than addressing healing at the bone-tendon junction (the 'enthesis'), a $3 billion annual U.S. market problem.
What's Tetrous, Inc.'s solution?
Tetrous makes EnFix, a biologic device made of demineralized bone fibers designed to promote enthesis (bone-to-tendon) tissue remodeling and integrate into current arthroscopic surgical techniques.
What makes Tetrous, Inc. different?
The company cites its proprietary Bone Textile technology, which it says produces long, strong fibers for better cell wicking/adhesion/proliferation versus the short, variable shavings from other processes, plus its FormLok technology for shape retention even when immersed in liquid.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.